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Bloch surface wavesWe report on hybrid inorganic/organic one-dimensional photonic crystal biochips sustaining Bloch sur-
face waves. The biochips were used, together with an optical platform operating in a label-free and flu-
orescence configuration simultaneously, to detect the cancer biomarker Angiopoietin 2 in a protein base
buffer. The hybrid photonic crystals embed in their geometry a thin functionalization poly-acrylic acid
layer deposited by plasma polymerization, which is used to immobilize a monoclonal antibody for highly
specific biological recognition. The fluorescence operation mode is described in detail, putting into evi-
dence the role of field enhancement and localization at the photonic crystal surface in the shaping and
intensification of the angular fluorescence pattern. In the fluorescence operation mode, the hybrid bio-
chips can attain the limit of detection 6 ng/ml.
 2018 Elsevier Ltd. All rights reserved.1. Introduction
Bloch surface waves (BSW) propagating at the interface
between a one dimensional photonic crystal (1DPC) and an exter-
nal medium [1,2] have been suggested for label-free biosensors
[3,4]. When used in a classical Kretschmann-Raether [5] total
internal reflection (TIR) configuration, similar to surface plasmon
resonance (SPR) sensing schemes [6], the BSW biochips feature
very low angular resonance widths compared to that of SPR, due
to the low losses in the dielectric stacks [7]. The optimization of
the 1DPC stack, in terms of geometry and materials, offers the pos-
sibility to improve the label-free limit of detection (LoD) [8].
Moreover, the strong field localization and enhancement at the
1DPC surface favor utilizing BSW coupled fluorescence emission
[9]. Coupling the label-free operation to a second detection scheme
relying on the emission of fluorescent labels can lead to a comple-
mentary analysis and a decrease of the LoD [10,11].
We report here on the application of a combined label-free and
fluorescence biosensing platform [12] to the detection of the
Angiopoietin-2 cancer biomarker in buffer solutions. The platform
makes use of disposable biochips fabricated by depositing 1DPC
onto injection molded plastic substrates. Here the 1DPC is
constituted by an inorganic multilayer that is topped by an organicnanometric layer providing the chemical functionalization of the
biosensor’s surface. For biosensing platforms based on the resonant
excitation and detection of surface electromagnetic modes, such as
surface plasmon resonance (SPR) [6], the possibility to embed the
organic functionalization layer in the biosensor’s structure and to
tune the 1DPC geometry permits to keep the resonance inside
the excitation/detection angular windows, while optimizing the
sensitivity. In SPR, as an example, the deposition of a thin organic
layer on a gold coated biochip shifts the SPR outside the usually
narrow angular operation window, without any possibility to com-
pensate by changing the thickness of the gold layer.
With respect to our previously published results [13–16], this is
the first time we report on cancer biomarkers detection assays
with a combined label-free and fluorescence platform and making
use of 1DPC hybrid biochips with a polymeric surface chemical
functionalization.2. BSW biochips
The geometry of the 1DPC used in this study is shown in Fig. 1a.
A dielectric multilayer was directly deposited on a prismatic
organic substrate (TOPAS, ns = 1.530) by plasma ion assisted depo-
sition (PIAD) under high vacuum conditions [17]. Then the multi-
layer was coated with an organic poly-acrylic acid (ppAA)
functional thin film by a plasma polymerization technique and
making use of a plasma enhanced chemical vapour deposition
reactor [18]. The geometry of the underlying inorganic part of
Fig. 1. (a) 1DPC geometry including the polymer functional ppAA film (not to scale). Sketches of the label-free (b) and fluorescence (c) modes of operation. (d) TIR angular
reflectance profile, with the biochip in buffer. (e) Fluorescence emission at the end of an assay where Ang2 was detected (blue curve) and before starting the experiment
(black curve). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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functional film/layer, the characteristics of the overall 1DPC are
optimized for both label-free and fluorescence sensing.
Besides being used to tune the BSW biochip performance [19],
the thin organic functional layer permits to covalently graft and
immobilize the proteins that are needed to provide the specificity
of the biosensor. ppAA thin coatings are a convenient choice for
surface chemical functionalization since they do not affect the
chemical properties of the biosensors, are conformal, do not need
any specific surface pre-treatment for adhesion and can provide
different density of functional groups, wettability and chemical
stability by simply varying the deposition process parameters [20].
The inorganic part of the 1DPC is constituted of SiO2, Ta2O5 and
TiO2, with complex refractive indices: n(SiO2) = 1.474 + j5  106,
n(Ta2O5) = 2.160 + j5  105, n(TiO2) = 2.28 + j1.8  103 at k0 = 6
70 nm [17]. Starting from the plastic substrate, the multilayer is
constituted by a first SiO2 layer, which improves the reliability of
the overlaying 1DPC, two Ta2O5/SiO2 bilayers and a top TiO2 layer.
The thicknesses of the layers are: d(SiO2) = 275 nm, d(Ta2O5) = 120
nm, and d(TiO2) = 20 nm.
The thickness of the ppAA thin topping layer was estimated by
atomic force microscopy and is d(ppAA)  40 nm and the refractive
index is n(ppAA) = 1.52, obtained by spectroscopic ellipsometry
[18].
After chemical functionalization and bio-conjugation, a plastic
cover with a soft polymer layer defining a fluidic channel (800
µm wide, 100 µm high, and 27 mm long) is clicked on top of the
biochip and permits the injection of fluids for the analysis [12].
3. Read-out configuration
The BSW biochips are mounted in an optical platform and are
used in either a label-free or in a fluorescence mode of operation,
as shown schematically in Fig. 1b and c, respectively. For the sake
of simplicity, in the figures, we do not show the optical compo-
nents that are used to focus and image the light beams; for a com-
plete description of the optical layout of the platform one can refer
to our precedent work [12]. In particular, the optical system is
based on the use of cylindrical optics and can simultaneously per-
form measurements in several different spots aligned along a line
over the biochip surface. The rows and columns of the CCD camera
(Apogee Ascent with Sony ICX814 sensor) are then used, respec-
tively, for either angular imaging (3388 pixel) or spot imaging
(2712 pixel).
In the label-free operation, the BSW biochip is illuminated
through a prism coupler in TIR conditions [6,21] by a TE polarizedand focused (FWHM above 4) laser beam at the wavelength k0 =
670 nm. The reflected beam is imaged on the CCD. As an example,
in Fig. 1d we show the TIR spectrum as a function of the incidence
angle inside the prism coupler h, in a 2.9 angular range (sampled
by 3388 pixel). Excitation of a BSW gives rise to a dip in the angular
reflectance spectrum at h0,BSW. The 1DPC was designed to operate
at h0,BSW = 69 and the thin TiO2 layer features were tuned to get
a narrow width and large depth of the resonant dip.
Fig. 1a illustrates (red curve) the distribution of the TE polarized
BSW energy density calculated at k0 and in resonance conditions.
The BSW is confined at the interface between the 1DPC and the
external medium, where the field decays exponentially with a pen-
etration length Lpen = 117 nm. Given its strong localization, the
BSW is very sensitive to refractive index perturbations in the vicin-
ity of the TiO2 layer and can be used to monitor protein binding
events at the biochip surface, as revealed by the shift of the reso-
nant dip.
In the fluorescence operation, the BSW biochip is excited in TIR
conditions at an angle hEXC by a TE polarized and slightly focused
(FWHM = 0.64) laser beam at the wavelength kEXC = 635 nm,
matching the absorption peak of the specific dye label that we
selected for the biological assays (Dylight 650). The effect of the
BSW excitation on fluorescence emission is twofold. On one-
hand, if hEXC is such that a resonant excitation condition of a
BSW at kEXC is achieved, the excitation intensity is enhanced at
the 1DPC surface, giving rise to an increased fluorescence emission.
On the other hand, the emission at kEM > kEXC of the dye-labelled
biomolecules possibly captured and excited at the biochip surface,
given the large BSW local density of the states [22], is channelled to
the BSW modes, which then are radiated through the substrate, as
shown in Fig. 1c.
As an example, Fig. 1e shows the angular emission spectrum
recorded by the CCD in a 8 angular range; such a wider range
is obtained by inserting a cylindrical zoom lens in the detection
system. Given that the 1DPC sustains both TE and TM polarized
BSW, with different dispersions, the emission is characterized
by two angularly separated TE and TM bands. For each band, each
angle corresponds to a different wavelength inside the emission
spectrum of Dylight 650. In Fig. 1e, the black curve is the mea-
surement for an unlabelled biochip, and accounts for the back-
ground signal captured by the CCD due to either stray light
from the excitation beam or intrinsic BSW coupled fluorescence
of the 1DPC materials. In all experiments reported below such a
background was always subtracted from the fluorescence signal
in the presence of labels, which is given by the blue curve shown
in Fig. 1e as an example.
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The ppAA coated 1DPC (Fig. 2a) were chemically treated (15
min) to activate the ACOOH groups with a solution of sulfo-NHS
(N-hydroxysulfosuccinimide, Thermo Scientific) and EDC (1-ethy
l-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, Thermo
Scientific) in a BupH MES (2-(N-morpholino)ethanesulfonic acid,
Thermo Scientific) buffer at pH 4.7 (Fig. 2b), followed by a washing
step in BupH MES and Dulbecco’s Phosphate Buffer Saline buffer
(referred to as ‘‘B” below) at 10 mM (D-PBS 1X).
Two separated signal and reference regions were defined on the
activated-ppAA 1DPC by means of a hydrophobic marker, where
either protein G (PtG, 0.5 mg/ml, Thermo Scientific) or bovine
serum albumin (BSA, 10 mg/ml, Sigma-Aldrich), dissolved in D-
PBS 1X, were incubated for 1 h at ambient temperature (AT),
respectively (Fig. 2c). Subsequently, the biochip was immersed in
a BSA solution (10 mg/ml in B) to block the remaining reactive sites
(overnight at 4 C). At the end, on the biochip surface there are a
signal region (PtG), which is capable to bind and orient the capture
antibodies, and a reference region (BSA), which is biochemicallyFig. 2. (a? d) Subsequent steps of the direct approach for the bio-conjugation of protei
assay format used in all experiments performed in this work.inert (Fig. 2d). Immediately before their use in a detection assay,
the surface of the biochips was treated with a regeneration solu-
tion made of glycine (20 mM, Sigma-Aldrich) in deionized water
and hydrogen chloride (HCl) with a pH of 2.5 for 10 min at AT, to
remove any adlayer formed during the BSA blocking step.
In the sandwich assays the target molecule was a Recombinant
Human Angiopoietin 2 (Ang2, 623-AN, R&D Systems) spiked in a
modified buffer, acting as a protein base buffer, consisting in a
solution of D-PBS 1X + 0.1 wt% BSA (referred to as ‘‘MB” below).
To specifically detect the presence of Ang2, a monoclonal anti-
human Ang2 antibody (a-Ang2, MAB0983, R&D Systems) was used
as a capturing element (Fig. 2e). After the interaction with the Ang2
sample (Fig. 2f), a specific biotinylated-detection Anti-Ang2 anti-
body (a-Ang2⁄, BAF623, R&D Systems) binds to Ang2 and provides
biotinylated characteristics to the signal region (Fig. 2g). Finally,
labelling takes place by the interaction with a solution of neutra-
vidin labelled with fluorophores emitting at kEM = 670 nm
(NeutrAvidin DyLight 650, N650, ThermoScientific). Neutravidin
was selected for its high affinity to biotin, therefore enabling detec-
tion of the a-Ang2⁄/Ang2 complex (Fig. 2h).ns (PtG, BSA) to the ppAA-loaded 1DPC surface prior to the assay. (e? h) Sandwich
Fig. 4. Average fluorescence emission signals from the labelled antibody-antigen
complexes at the 1DPC surface for the signal (S, blue) and reference (R, grey) regions
(7 spots). The fluorescence signals were recorded at the end of a 50 ng/ml (a) and a
10 ng/ml (b) Ang2 sandwich assay. The error bars are the standard error of the
mean. (For interpretation of the references to colour in this figure legend, the reader
is referred to the web version of this article.)
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In Fig. 3 we show the sensograms recorded in label-free mode
during an Ang2 cancer biomarker detection assay. The angular
position of the BSW resonant dip h0,BSW is tracked as a function
of time. The two curves are the result of averaging the signals mea-
sured in 7 different spots in either the signal region (PtG) or the
reference region (BSA). Each spot corresponds to 100 CCD camera
rows.
The assay starts in MB and proceeds according to the following
steps. First we inject a solution of a-Ang2 (30 lg/ml in MB) and
incubate for 25 min. After such a step, the biochip is ready to be
used to detect the biomarkers. In the specific case of Fig. 3, we
injected a solution of Ang2 (50 ng/ml in MB) and incubated for
50 min. This ends up the label-free part of the assay. For the subse-
quent fluorescence part of the assay, we inject a solution of a-
Ang2⁄ (2 lg/ml in MB) and incubate for 27 min. Then, we change
the running buffer from MB to B and inject a solution of N650
(10 lg/ml in B) and incubate for 13 min. For all analytes, we
injected 100 ll of the solutions and recirculated 50 ll by pumping
back and forth. All incubation steps are followed by a washing step
carried out by injecting 500 ll of either MB or B. In all cases the
injection flow rate was 4 ll/s.
Fig. 3a shows a drift of the label-free signals in both the refer-
ence and signal regions, due to changes of the temperature, pres-
sure and laser wavelength k0. Such drifts are ruled out by
subtracting the two curves, giving rise to the differential signal
shown in Fig. 3b. Besides giving access to label-free detection of
the Ang2 biomarker (if concluded), the differential signal permits
to monitor all phases of the subsequent fluorescence assay, which
is not possible in common techniques, such as ELISA for example.
In particular one can monitor the correct immobilization of the
capture antibodies, the quality and stability of the blocking agents,
the presence of biochip defects or of fluid flow anomalies.
For what is concerning the fluorescence assay, in Fig. 4a we
show the angular emission spectra recorded at resonant excitation
for the Ang2 detection assay described above (50 ng/ml in MB).Fig. 3. (a) Label-free sensograms recorded during an Ang2 sandwich assay in the
signal (S, blue) and reference (R, grey) regions (average of 7 spots). The error bars
are the standard error of the mean. (b) The red curve is the differential signal with
error bars every 2 min. (For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this article.)Fluorescence emission in B was measured in the two signal (blue
data) and reference regions (grey data), after incubating the
N650 solution and washing. The curves were obtained by averag-
ing the signals in the same 7 spots used for the label-free measure-
ment. In both cases the spectra were corrected by subtracting the
background fluorescence (similar to Fig. 1e) measured immedi-
ately before injecting the N650 solution and averaged on the same
spots.
In all fluorescence assays, the angular emission spectrum under
resonant excitation conditions is determined according to the fol-
lowing procedure. The incidence angle of the fluorescence excita-
tion laser hEXC is scanned in a convenient angular range around
the BSW resonant dip hEXC,BSW at kEXC and fluorescence images
are acquired in a sequence by the CCD camera during the scan.
Thanks to the dispersion of the BSW mode, hEXC,BSW > h0,BSW and
lays outside the CCD angular field of view (right hand side in
Fig. 4). In the platform, scanning of hEXC is achieved by laterally
shifting the fluorescence excitation laser while keeping fixed the
focusing lens (not shown in Fig. 1).
As an example, in Fig. 5a we show a set of angular emission
spectra recorded for different values of hEXC, from off-resonance
to resonance. The background subtracted spectra refer to the
Ang2 detection assay at 50 ng/ml and to one single spot within
the signal region on the biochip. Clearly, when approaching hEXC
(BSW) the intensity of the angular emission increases up to a max-
imum (red curve), due to the BSW intensity enhancement at the
1DPC surface. This is confirmed by Fig. 5b, which shows that the
total BSW emitted power, i.e. the integral of the curves in Fig. 5a,
is peaked around hBSW,EXC. For that specific spot, we therefore
assign as a fluorescence angular spectrum under resonant excita-
tion the maximum curve (red) among those collected for that spot
during the scan.
Owing to the inhomogeneities of the bare 1DPC and to the dif-
ferent degree of binding, resonant excitation can take place in each
spot at a different hBSW,EXC. Therefore, the same procedure is
repeated by analyzing the series of CCD images and selecting for
each spot the most intense angular emission spectrum. Finally,
Fig. 5. (a) Background subtracted fluorescence intensity at the end of a 50 ng/ml
Ang2 assay for several different hEXC of the fluorescence excitation laser at kEXC. The
maximum fluorescence intensity obtained under resonant conditions at hEXC, BSW is
plotted in red in a CCD angular range of [0, 2200] pixels. (b) Integrated fluorescence
intensity in proximity of the hEXC, BSW and Lorentzian fit (red curve). (For
interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 6. (a) Bar plot of the integrated fluorescence intensities W for both assays. In
the inset it is represented the linear dependence of WDIFF as a function of the Ang2
concentration.
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a given number of spots in the signal and reference regions, to gen-
erate the curves shown in Fig. 4a. During such a procedure, the
value of h0,BSW for each spot that is extracted from the label-free
measurement is used to determine, spot by spot and making use
of the BSW dispersion, the position of the hEXC scanning window.
In Fig. 4b, we show the results for an Ang2 detection assay at 10
ng/ml in MB, obtained according to the same procedures. Also in
this case the response of the signal and reference regions can be
clearly distinguished in the limit of the measurement noise.6. Discussion
The sensograms shown in Fig. 3 indicate that label-free detec-
tion of Ang2 at 50 ng/ml cannot be concluded. The growth of the
differential signal during the Ang2 solution incubation cannot be
distinguished from the residual slope, which characterizes the
whole sensogram. Such a residual signal could be due to BSA from
the MB binding non-specifically to the biochip surface. The same is
true, obviously, also for the assay at 10 ng/ml (not shown). There-
fore, the label-free LoD of the present ppAA based BSW biochips is
surely larger than 50 ng/ml. Such a limitation is also related to the
efficiency of the chemical surface functionalization. As a compar-
ison, the same BSW biochips with a different surface chemistry,
based on 3-Aminopropyl)triethoxysilane (APTES) with glutaralde-
hyde (GAH) as cross-linker [23] showed the same limitation for
label-free Ang2 detection [24], whereas, in case the PtG immobi-
lization step is dropped, they were demonstrated to label-free
detect a different biomarker (VEGF) at 50 ng/ml with an estimated
LoD of 11.5 ng/ml [12].
Despite the limitations, the label-free signal provides useful
real-time information on the assay development. Fig. 3 shows that
PtG is efficiently binding the capture antibody in the signal region
of the biochip, whereas BSA blocking guarantees a good anti-
fouling action in the reference region. From the differential shift
of the BSW resonance after the a-Ang2 incubation one can evalu-
ate, making use of the label-free sensitivity of the biochips [11],
that the a-Ang2 surface density is (65 ± 2) ng/cm2. The residual
slope that is observed in the MB, in which the BSA concentration
is very large (about 1 mg/ml), indicates that blocking could be
improved by using different and smaller passivation agents, suchas caseine for example. The sensorgrams also show that there are
no instabilities of the microfluidic environment (bubbles, leaks,
blockage of the microchannel), guaranteeing homogeneity during
the assay steps (injection, recirculation, washing).
It is therefore clear that Ang2 detection at low concentration
with the present platform needs to be accessed by fluorescence
detection.
Fig. 4 shows that Ang2 detection in the fluorescence mode is
achieved in both assays, at 50 ng/ml and 10 ng/ml. The intensity
in the signal region is well distinguished from that in the reference
region. Such a result is obtained thanks to the BSW enhanced flu-
orescence operation. Fig. 5b shows that the intensity of the fluores-
cence emission is increased by a factor 45 when operating at
resonant excitation. Fig. 4 shows that the fluorescence collection
efficiency is improved due to the fact that the emission is confined
in an angular interval of about 5.
The result of the assays is better evidenced in Fig. 6, where the
bar plot shows the experimental values of W for both assays. We
conclude that Ang2 was detected at 10 ng/ml, within the error
limit. In the inset of Fig. 6, we plot the WDIFF values as a function
of the concentration c, showing that WDIFF scales linearly with c,
which is expected in the limit of low concentration. Such a plot
can be used to retrieve an estimation of the fluorescence LoD, by
extrapolating the linear dependency down to the level correspond-
ing to three times the standard deviation of the measurement at
lowest c. We find that the fluorescence LoD is 6 ng/ml. Again such
a value can be compared to that obtained with the same biochips
and APTES chemistry and without PtG, which is 0.65 ng/ml for
the same Ang2 biomarker [14].
The results obtained in both the label-free and fluorescence
mode of operation seem to confirm that, using the same BSW bio-
chips, the immobilization protocol based on ppAA/PtG/a-Ang2 is
less efficient that a protocol based on APTES/GAH/a-Ang2.7. Conclusions
In conclusion we demonstrated that the hybrid ppAA/inorganic
BSW biochips can be efficiently used to detect the Ang2 biomarker
at low concentration in a modified buffer, when operating the plat-
form in the fluorescence mode where BSW coupled fluorescence
excitation and emission is exploited. In particular, the plasma poly-
merized poly-acrylic acid organic top layer is shown to immobilize
PtG and the capture antibody at the surface of the biochips, with a
surface density of the antibodies as large as (65 ± 2) ng/cm2. In the
test assays, the BSW biochips were used to directly detect in the
fluorescence mode Ang2 at the concentration 10 ng/ml with an
232 A. Sinibaldi et al. / Optics and Laser Technology 102 (2018) 227–232estimated limit of detection of 6.0 ng/ml. Comparison of such a
result to our precedent achievements indicates that such a limit
of detection of hybrid biochips can be improved by dropping the
PtG immobilization step and immobilizing the capture antibodies
directly on the ppAA functional layer. This would permit to obtain
hybrid biochips with limit of detection below the threshold for
Ang2 concentration in healthy patients (5 ng/ml) and taking
advantage of the versatility of the plasma polymerization
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